Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …

Prostate cancer is the most commonly diagnosed cancer in men worldwide, making up 21%
of all cancer cases. With 345,000 deaths per year owing to the disease, there is an urgent …

The tumor-associated antigen STEAP1 is a potential therapeutic target that is expressed in
most prostate tumors and at increased levels in metastatic castration-resistant prostate …

Prostate-specific membrane antigen (PSMA) is an important cell surface target in prostate
cancer. There are limited data on the heterogeneity of PSMA tissue expression in metastatic …

Prostate-specific membrane antigen (PSMA) as a transmembrane protein is overexpressed
by prostate cancer (PC) cells and is accessible for binding antibodies or low-molecular …

Immunotherapy has emerged as an important approach for cancer treatment, but its clinical
efficacy has been limited in prostate cancer compared to other malignancies. This review …

Immunotherapy has revolutionized and opened a new paradigm for cancer treatment. In the
era of immunotherapy and molecular targeted therapy, precision medicine has gained …

Background Despite advancements in managing metastatic clear cell renal carcinoma
(mccRCC) through antiangiogenic tyrosine kinase inhibitors and immunotherapy, there …

Prostate cancer (PCa) is a leading cause of cancer-related morbidity and mortality in men
globally. Despite improvements in the diagnosis and treatment of PCa, a significant …

ABSTRACT Introduction The prostate cancer (PCa) consist the most frequently diagnosed
malignancy of urogenital system in males. Traditionally, treatment of localized PCa was …